Al­tim­mune cuts he­pati­tis B pro­gram, high­lights mus­cle preser­va­tion on obe­si­ty drug in da­ta up­date

Al­tim­mune is end­ing its he­pati­tis B pro­gram fol­low­ing a tri­al fail­ure, rais­ing the stakes on its on­ly re­main­ing can­di­date in the pipeline — an in­jectable GLP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER